GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Price-to-Free-Cash-Flow

Telesis Bio (Telesis Bio) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Price-to-Free-Cash-Flow?

As of today (2024-04-25), Telesis Bio's share price is $0.32. Telesis Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.23. Hence, Telesis Bio's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Telesis Bio's Price-to-Free-Cash-Flow or its related term are showing as below:

TBIO's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.73
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Telesis Bio's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.25. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.23.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -19.20% per year.

During the past 5 years, Telesis Bio's highest 3-Year average Free Cash Flow per Share Growth Rate was -19.20% per year. The lowest was -19.20% per year. And the median was -19.20% per year.


Telesis Bio Price-to-Free-Cash-Flow Historical Data

The historical data trend for Telesis Bio's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Price-to-Free-Cash-Flow Chart

Telesis Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Telesis Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Telesis Bio's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, Telesis Bio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telesis Bio's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Telesis Bio's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Telesis Bio's Price-to-Free-Cash-Flow falls into.



Telesis Bio Price-to-Free-Cash-Flow Calculation

Telesis Bio's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.32/-1.229
=N/A

Telesis Bio's Share Price of today is $0.32.
Telesis Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Telesis Bio  (NAS:TBIO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Telesis Bio Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Telesis Bio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Telesis Bio (Telesis Bio) Business Description

Traded in Other Exchanges
N/A
Address
10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.
Executives
Gregory J. Herrema director 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers 10 percent owner GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p. 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider director, 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister director, 10 percent owner 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler officer: Chief Legal Officer C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson officer: Chief Technology Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson director, 10 percent owner, officer: President & CEO C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser officer: Chief Operating Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814